Valued at a market cap of $9.2 billion, Tempus AI (TEM) stock went public in June 2024. Since its initial public offering, ...

Ambry Genetics was the first commercial laboratory to begin offering clinical diagnostic exome sequencing testing in 2011 3, which may bring new hope to thousands of patients and families searching ...

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

Tempus AI stock is trading at a nosebleed valuation, and despite the compelling long-term upside, it's not worth investing at ...

Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, today announced new data to be presented at the 2025 American Society of ...

said that it is targeting $1.25 billion in revenues for the consolidated Tempus and Ambry Genetics for full-year 2025, which would represent an 80 percent growth year-on-year. During the first ...

The acquisitions of Ambry Genetics and Deep 6 AI are expected to have contributed to Tempus AI's strategic expansion during the first quarter of 2025. The acquisition of Ambry Genetics ...

Major acquisitions and partnerships have played a key role in Tempus AI’s market growth, solidifying its position in healthcare AI. The Ambry Genetics acquisition expanded its genomics division ...